Display options
Cite
Coventry BJ, Baume D, Lilly C. Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. Cancer Manag Res. 2015;7:93-103doi: 10.2147/CMAR.S76163.
Coventry, B. J., Baume, D., & Lilly, C. (2015). Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. Cancer management and research, 793-103. https://doi.org/10.2147/CMAR.S76163
Coventry, Brendon J, et al. "Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?." Cancer management and research vol. 7 (2015): 93-103. doi: https://doi.org/10.2147/CMAR.S76163
Coventry BJ, Baume D, Lilly C. Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. Cancer Manag Res. 2015 Apr 29;7:93-103. doi: 10.2147/CMAR.S76163. eCollection 2015. PMID: 25995649; PMCID: PMC4425244.
Copy Download .nbib Format: NLM
Share it on

Cancer Manag Res. 2015 Apr 29;7:93-103. doi: 10.2147/CMAR.S76163. eCollection 2015.

Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?.

Cancer management and research

Brendon J Coventry, Dominique Baume, Carrie Lilly

Affiliations

  1. Discipline of Surgery, Royal Adelaide Hospital, University of Adelaide, Adelaide, SA, Australia.

PMID: 25995649 PMCID: PMC4425244 DOI: 10.2147/CMAR.S76163

Abstract

BACKGROUND: Patients with advanced metastatic melanoma are often confronted with little prospect of medium- to longer-term survival by any currently available therapeutic means. However, most clinicians are aware of exceptional cases where survival defies the notion of futility. Prolonged survival from immunotherapies, including interleukin-2, vaccines and antibodies to cytotoxic lymphocyte antigen-4, and programmed death-1 receptor inhibitory monoclonal antibody, implies a role for immune system modulation. We aimed to identify cases where exceptional survival from advanced melanoma occurred prior to recent novel therapies to facilitate better understanding of this phenomenon.

METHODS: Cases of long-term survival of ≥3 years' duration (from diagnosis of metastatic disease) were identified from the database of one clinician; these cases were treated before the availability of newer immunotherapies, and they were documented and examined. A literature search for reported outcome measures from published studies using older and recent therapies for advanced melanoma was conducted to enable the comparison of data.

RESULTS: Eighteen cases were identified that identified survival of ≥3 years' duration from metastatic disease (12 American Joint Committee on Cancer [AJCC] Stage IV cases; six AJCC III cases) diagnosis. These were assessed and reported to detail the clinical course. Standard clinical prognostication methods predicted high risk of early mortality in those patients. No identifiable differences could be detected between these and other patients with similar patterns of disease. At evaluation, 17 patients (94%) had survived ≥5 years, and eleven patients (61%) had survived ≥10 years (range: 3-15 years). The median survival duration with metastatic disease was 11 years; 15 remained alive and three had died. Published studies of melanoma therapies were tabled for comparison.

CONCLUSION: The fact that 18 cases of exceptional survival in advanced melanoma were identified is remarkable in itself. Even with recent therapies, the factors for improved survival remain enigmatic; however, one apparent common denominator in most cases was the persistent use of repeated therapies to reduce tumor bulk, induce tumor necrosis, and/or cause immunostimulation. These cases are instructive, suggesting manipulation of an established, endogenous, existing immune response. These observations provide practical evidence that the course for any patient with advanced melanoma at the outset should be considered unpredictable, open to immunomanipulation, and thus not uniformly fatal. The findings were compared and interpreted with reported newer immunotherapeutic approaches.

Keywords: advanced melanoma; clinical responses; immunotherapy; prolonged survival

References

  1. J Clin Oncol. 2000 Jan;18(1):158-66 - PubMed
  2. Cancer J Sci Am. 2000 Feb;6 Suppl 1:S11-4 - PubMed
  3. J Clin Oncol. 2004 Mar 15;22(6):1118-25 - PubMed
  4. Cancer Control. 2005 Oct;12(4):223-9 - PubMed
  5. Vaccine. 2007 Sep 27;25 Suppl 2:B97-B109 - PubMed
  6. Ann Surg Oncol. 2008 Nov;15(11):3022-7 - PubMed
  7. J Am Acad Dermatol. 2009 May;60(5):872-5 - PubMed
  8. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  9. N Engl J Med. 2010 Aug 26;363(9):809-19 - PubMed
  10. Cancer Manag Res. 2010 Aug 17;2:197-211 - PubMed
  11. J Gastrointestin Liver Dis. 2010 Dec;19(4):453-5 - PubMed
  12. J Surg Oncol. 2011 Aug 1;104(2):111-5 - PubMed
  13. Clin Cancer Res. 2011 Jul 1;17(13):4550-7 - PubMed
  14. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  15. N Engl J Med. 2011 Jun 30;364(26):2547-8 - PubMed
  16. N Engl J Med. 2011 Jun 30;364(26):2517-26 - PubMed
  17. J Surg Oncol. 2011 Sep;104(4):420-4 - PubMed
  18. Clin Cancer Res. 2012 Apr 1;18(7):2039-47 - PubMed
  19. Lancet Oncol. 2012 Jun;13(6):589-97 - PubMed
  20. Ann Surg Oncol. 2012 Aug;19(8):2547-55 - PubMed
  21. N Engl J Med. 2012 Jun 28;366(26):2443-54 - PubMed
  22. N Engl J Med. 2012 Jun 28;366(26):2455-65 - PubMed
  23. N Engl J Med. 2012 Jul 12;367(2):107-14 - PubMed
  24. Cancer Manag Res. 2012;4:137-49 - PubMed
  25. Cancer Manag Res. 2012;4:215-21 - PubMed
  26. N Engl J Med. 2012 Nov;367(18):1694-703 - PubMed
  27. N Engl J Med. 2013 Jul 11;369(2):134-44 - PubMed
  28. N Engl J Med. 2013 Jul 11;369(2):122-33 - PubMed
  29. Cancer Manag Res. 2013 Aug 20;5:243-9 - PubMed
  30. Ther Adv Med Oncol. 2013 Sep;5(5):278-85 - PubMed
  31. N Engl J Med. 2014 Feb 13;370(7):599-609 - PubMed
  32. J Clin Oncol. 2014 Apr 1;32(10):1020-30 - PubMed
  33. J Surg Oncol. 2014 Jun;109(8):780-5 - PubMed
  34. Mayo Clin Proc. 2014 Apr;89(4):429-33 - PubMed
  35. J Immunother Cancer. 2014 Apr 15;2:9 - PubMed
  36. Cancer. 1984 Mar 15;53(6):1299-305 - PubMed
  37. J Clin Oncol. 1995 Dec;13(12):2895-9 - PubMed
  38. Cancer. 1997 Jun 15;79(12):2345-53 - PubMed

Publication Types